237430-03-4
237430-03-4 structure
- Name: Alsterpaullone
- Chemical Name: Alsterpaullone
- CAS Number: 237430-03-4
- Molecular Formula: C16H11N3O3
- Molecular Weight: 293.277
- Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
- Create Date: 2018-04-05 08:00:00
- Modify Date: 2026-07-08 11:25:37
-
Alsterpaullone (9-Nitropaullone;NSC 705701) is a potent cyclin-dependent kinases (CDK) inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to glycogen synthase kinase-3 alpha/beta (GSK-3alpha/GSK-3beta) with an IC50 of 4 nM, with antitumor activity and potential for the treatment of neurodegenerative and proliferative disorders[1].
| Name | Alsterpaullone |
|---|---|
| Synonyms |
9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one
Indolo[3,2-d]benzazin-6(5H)-one, 7,12-dihydro-9-nitro Alsterpaullone - - Calbiochem 9-Nitropaullone ALSTERPAULLONE, 10 mM in DMSO 7,12-Dihydro-9-nitroindolo[3,2-d]benzazin-6(5H)-one Alsterpaullone (9-Nitropaullone 9-nitro-7,12-dihydrobenzo[2,3]azino[4,5-b]indol-6(5H)-one CDK5,GSK-3,p35,NSC-705701,9-Nitropaullone,NSC705701,ALSTERPAULLONE,Glycogen synthase kinase-3,cyclin E,Glycogen synthase kinase 3,Cyclin dendent kinase,inhibit,NSC 705701,antitumor,CDK2,cyclin A,cyclin B,Inhibitor,CDK,Apoptosis,CDK1,neurodegenerative Alsteropaullone 9-nitro-7,12-dihydro-5H-indolo[3,2-d]benzazin-6-one 9-NITRO-7,12-DIHYDROINDOLO-[3,2-D]BENZAZIN-6-ONE 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one Alsterpaullone, cyclin-dendent kinase (CDK) and GSK-3beta inhibitor 9-NITRO-7,12-DIHYDROINDOLO-[3,2-D]BENZAZIN-6(5H)-ONE ALSTERPAULLONE 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one |
| Description | Alsterpaullone (9-Nitropaullone;NSC 705701) is a potent cyclin-dependent kinases (CDK) inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to glycogen synthase kinase-3 alpha/beta (GSK-3alpha/GSK-3beta) with an IC50 of 4 nM, with antitumor activity and potential for the treatment of neurodegenerative and proliferative disorders[1]. |
|---|---|
| Related Catalog | |
| Target |
Cdk1/cyclin B:35 nM (IC50) cdk2/cyclin A:15 nM (IC50) CDK2/Cyc E:200 nM (IC50) CDK5/p35:40 nM (IC50) GSK-3α:4 (IC50) GSK-3β:4 nM (IC50) |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 651.5±45.0 °C at 760 mmHg |
| Molecular Formula | C16H11N3O3 |
| Molecular Weight | 293.277 |
| Flash Point | 347.8±28.7 °C |
| Exact Mass | 293.080048 |
| PSA | 90.71000 |
| LogP | 3.55 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.738 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2933990090 |
|
~32%
237430-03-4 |
| Literature: Zaharevitz, Daniel W.; Gussio, Rick P.; Jalluri, Ravi K.; Sausville, Edward A.; Kunick, Conrad; Meijer, Laurent Patent: US2002/42412 A1, 2002 ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |